LIDDS secures financing of up to 40.8 MSEK to create foundation for new partnerships based on the NanoZolid® technology
Summary
UPPSALA, SWEDEN LIDDS AB (publ) announced today that the company has entered into a convertible note agreement with Nice & Green (N&G), a Swiss specialty investor with significant experience from the life science industry. LIDDS is also seeking to strengthen and complement its ownership structure with both Swedish and international institutional investors and the aim is to secure financing with as low dilution of current shareholders as possible. Based on the closing price on 21 February 2022, the dilution from one tranche would be approximately 4.3 percent.N&G is a privately held Swiss investment firm providing innovative and tailor-made alternative financing solutions for small and mid-sized companies to facilitate their growth ambitions. "LIDDS has committed to call an Extraordinary General Meeting to receive an authorization for the Board of Directors to resolve to issue contertible notes pursuant to the agreement. The information was submitted for publication, through the agency of the aforementioned contact persons, on February 22, 2022 at 15.45 CET.LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid\xae.